Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | MPC2 | O95563 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SOD1 | P00441 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.30 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6930220 | 1.00 | PPARG (0.64) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL6928300 | 1.00 | PPARG (0.64) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL21504696 | 0.89 | PPARG (0.53) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL6930478 | 0.89 | PPARG (0.50) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL12628859 | 0.88 | PPARG (0.50) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL14408623 | 0.88 | PPARG (0.50) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL23836845 | 0.87 | PPARG (0.66) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL18541509 | 0.87 | PPARG (0.66) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL6931166 | 0.85 | PPARG (0.48) | PPARGCYP3A4RXRAMPC2CYP2C8 | |
| SCHEMBL6931096 | 0.85 | PPARG (0.48) | PPARGCYP3A4RXRAMPC2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211682-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | DEUTERX, LLC | 2022-07-07 | — | — | US | disclosed |
| US-11123336-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | POXEL SA (FR) | 2021-09-21 | — | — | US | disclosed |
| US-10265305-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | POXEL SA (FR) | 2019-04-23 | — | — | US | disclosed |
| US-20180133204-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | POXEL SA (FR) | 2018-05-17 | — | — | US | disclosed |
| US-9833445-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | DEUTERX, LLC (US) | 2017-12-05 | — | — | US | disclosed |
| EP-3202401-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Octeta Therapeutics, LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20170049762-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | POXEL SA (FR) | 2017-02-23 | — | — | US | disclosed |
| EP-2512470-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OCTETA THERAPEUTICS LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| WO-2011084453-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084459-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084456-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011075514-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20090143441-A1 | Combination therapies of Thiazolidinedione analogues | METABOLIC SOLUTIONS DEVELOPMENT COMPANY | 2009-06-04 | — | — | US | disclosed |
| US-20090143441-A1 | Combination therapies of Thiazolidinedione analogues | METABOLIC SOLUTIONS DEVELOPMENT COMPANY | 2009-06-04 | — | — | US | disclosed |
| US-20090143442-A1 | Thiazolidinedione analogues | ALZHEIMER DRUG DISCOVERY FOUNDATION | 2009-06-04 | — | — | US | disclosed |
| US-20090143442-A1 | Thiazolidinedione analogues | ALZHEIMER DRUG DISCOVERY FOUNDATION | 2009-06-04 | — | — | US | disclosed |
| US-20090137638-A1 | Thiazolidinedione analogues | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC | 2009-05-28 | — | — | US | disclosed |
| US-20090137638-A1 | Thiazolidinedione analogues | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265305-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | SLC5A2, PPARD, DPP4 | PPARG 10/4885CYP3A4 108/4885RXRA 213/4885 |
| US-20090143442-A1 | Thiazolidinedione analogues | PPARD, GLP1R, PPARG | PPARG 3/4885CYP3A4 727/4885RXRA 435/4885 |
| US-20090143441-A1 | Combination therapies of Thiazolidinedione analogues | GLP1R, PPARD, SLC5A2 | PPARG 5/4885CYP3A4 1170/4885RXRA 218/4885 |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARG 2/4885CYP3A4 685/4885RXRA 27/4885 |
| US-20090137638-A1 | Thiazolidinedione analogues | SLC5A2, GLP1R, SLC5A1 | PPARG 6/4885CYP3A4 1017/4885RXRA 346/4885 |
| US-20220211682-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SLC5A2, PPARD, DPP4 | PPARG 10/4885CYP3A4 108/4885RXRA 213/4885 |
| US-20180133204-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SLC5A2, PPARD, DPP4 | PPARG 10/4885CYP3A4 108/4885RXRA 213/4885 |
| US-11123336-B2 | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same | SLC5A2, PPARD, DPP4 | PPARG 10/4885CYP3A4 108/4885RXRA 213/4885 |
| US-20170049762-A1 | 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | SLC5A2, PPARD, DPP4 | PPARG 10/4885CYP3A4 108/4885RXRA 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.